Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
AbelZeta Inc.
Study ID
NCT07875413
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Diffuse Large B Cell Lymphoma (DLBCL)
  • FL
  • HGBL
  • HGBL With MYC and BCL2 and/or BCL6 Rearrangements
  • High Grade B Cell Lymphoma
  • LBCL
  • Large B Cell Lymphoma
  • PMBCL
  • Primary Mediastinal B Cell Lymphoma
  • Relapse Diffuse Large B Cell Lymphoma
  • Transformed Follicular Lymphoma (TFL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Prizloncabtagene Autoleucel — BIOLOGICAL
    An Autologous anti-CD19/CD20 chimeric antigen receptor T-cell therapy

Study Details

This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen receptor T cells following lymphodepleting chemotherapy in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma post FDA approved, commercially available CAR T-cell therapy Approximately 50 participants will undergo leukapheresis, lymphodepletion with fludarabine and cyclophosphamide, and infusion of Prizlon-cel. Participants will be followed for 24 months (approximately 2 years) to evaluate efficacy, safety, CAR T-cell persistence, pharmacokinetics/pharmacodynamics, and biomarkers. Long-term safety follow-up for gene therapy-related events will continue for up to 15 years following CAR T-cell infusion.

Key Dates

First listed
Oct 15, 2026
Start date
May 31, 2027
Status verified
Oct 2026
Primary completion
Jun 30, 2029
Completion
Dec 31, 2030

Study Design

Enrollment
55 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Prizlon-cel
    Participants will receive: • Leukapheresis • Fludarabine • Cyclophosphamide • Single intravenous infusion of Prizlon-cel.

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: Through Month 24 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Research SiteGilbertArizona85234-
Research SiteLa JollaCalifornia92037-

Related Studies